Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms. Academic Article uri icon

Overview

MeSH

  • Erlotinib Hydrochloride
  • Humans
  • Male
  • Middle Aged
  • Mucin 5AC

MeSH Major

  • Adenocarcinoma, Mucinous
  • Antineoplastic Agents
  • Carcinoma, Pancreatic Ductal
  • Pancreatic Neoplasms
  • Quinazolines

abstract

  • Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8). ©2011 AACR.

publication date

  • April 2011

has subject area

  • Adenocarcinoma, Mucinous
  • Antineoplastic Agents
  • Carcinoma, Pancreatic Ductal
  • Erlotinib Hydrochloride
  • Humans
  • Male
  • Middle Aged
  • Mucin 5AC
  • Pancreatic Neoplasms
  • Quinazolines

Research

keywords

  • Clinical Trial, Phase II
  • Journal Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4492452

Digital Object Identifier (DOI)

  • 10.1158/1940-6207.CAPR-10-0373

PubMed ID

  • 21464031

Additional Document Info

start page

  • 512

end page

  • 513

volume

  • 4

number

  • 4